Cellectis (NASDAQ: CLLS) will report its financial results for the second quarter of 2026, ending June 30, 2026, on Thursday, August 6, 2026. The announcement is scheduled for release after the close of the US market. This disclosure provides investors with an update on the clinical-stage biotechnology company’s progress in developing gene-edited cell and gene therapies.

The press release detailing the quarterly performance will be available in the Investors section of Cellectis’ official website. The company has stated it will not host a conference call to discuss these results. Instead, the investor relations team remains available for questions at investors@cellectis.com .

Company Overview

Cellectis utilizes a pioneering gene-editing platform to develop life-saving cell and gene therapies. The company employs an allogeneic approach for CAR T immunotherapies in oncology, focusing on off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. Additionally, Cellectis maintains a platform to develop gene therapies in other therapeutic indications.

With in-house manufacturing capabilities, Cellectis controls the cell and gene therapy value chain from start to finish. The company is headquartered in Paris, France, with additional locations in New York and Raleigh, NC. It is listed on the Nasdaq Global Market under the ticker CLLS and on Euronext Growth under the ticker ALCLS.

Contact Information

For further information regarding the announcement or general inquiries, stakeholders may refer to the following contacts:

What the Numbers Show

As this announcement pertains to the scheduling of financial results rather than the results themselves, no financial metrics such as revenue, net profit, or cash position are disclosed in this filing. The material value of this release lies in the confirmed date for the upcoming earnings disclosure, allowing investors to plan their review of Cellectis’ operational and financial performance for the period ended June 30, 2026.

Cellectis, a clinical-stage biotechnology company, held its shareholders general meeting on June 25, 2026, at 2:30 p.m. CET in Paris, France. During the meeting, approximately 55.84% of voting rights were exercised, leading to the adoption of resolutions 1 through 29. Resolution 30 was rejected, aligning with the recommendations of the board of directors.

Voting Outcomes

The meeting addressed 30 resolutions in total, with the majority approved by shareholders. The rejection of resolution 30 was consistent with the board's guidance. The detailed results of the vote and the resolutions are accessible on Cellectis’ official website.

Company Overview

Cellectis specializes in gene-editing platforms to develop life-saving cell and gene therapies. The company employs an allogeneic approach for CAR T immunotherapies in oncology, focusing on off-the-shelf and ready-to-use gene-edited CAR T-cells. With in-house manufacturing capabilities, Cellectis controls the cell and gene therapy value chain end-to-end.

Corporate Details

The company’s operations span multiple therapeutic indications, leveraging its proprietary platform to advance treatments for cancer and other diseases. Cellectis remains one of the few gene editing companies with full control over the therapy development process.